NCT07110584View on ClinicalTrials.gov

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2031

Study Completion Date

June 30, 2031

Conditions
Advanced Tumors
Interventions
DRUG

MDX2004

MDX2004 intravenous infusion

Trial Locations (1)

2298

RECRUITING

Calvary Mater Newcastle, Waratah

All Listed Sponsors
lead

ModeX Therapeutics, An OPKO Health Company

INDUSTRY

NCT07110584 - Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors | Biotech Hunter | Biotech Hunter